CRISPR Therapeutics AG
CRSPCRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 3, 2026
5dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CRSP Earnings Report
EPS Est: $-1.10 | FQ end 2026-06
How CRSP's past catalysts played out
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CRISPR Therapeutics AG's drug pipeline?→
CatalystAlert tracks 2 drug candidates in CRISPR Therapeutics AG's (CRSP) pipeline across Phase 2. Its lead program is CTX131 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CRISPR Therapeutics AG's next FDA catalyst?→
CRISPR Therapeutics AG's (CRSP) next tracked catalyst is a Earnings expected August 3, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRSP biotech catalysts?→
Add CRSP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CRISPR Therapeutics AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.